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by significant morphological and ultrastructural
changes in both erythrocytes and in thrombin-
generated fibrin: implications for diagnostics
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We have noted in previous work, in a variety of inflammatory diseases, where iron dysregulation occurs, a strong
tendency for erythrocytes to lose their normal discoid shape and to adopt a skewed morphology (as judged by
their axial ratios in the light microscope and by their ultrastructure in the SEM). Similarly, the polymerization of
fibrinogen, as induced in vitro by added thrombin, leads not to the common ‘spaghetti-like’ structures but to dense
matted deposits. Type 2 diabetes is a known inflammatory disease. In the present work, we found that the axial
ratio of the erythrocytes of poorly controlled (as suggested by increased HbA1c levels) type 2 diabetics was
significantly increased, and that their fibrin morphologies were again highly aberrant. As judged by scanning
electron microscopy and in the atomic force microscope, these could be reversed, to some degree, by the addition
of the iron chelators deferoxamine (DFO) or deferasirox (DFX). As well as their demonstrated diagnostic significance,
these morphological indicators may have prognostic value.
Keywords: Type II diabetes, Erythrocytes, Deferoxamine, DeferasiroxIntroduction
Type II diabetes mellitus causes an ever-increasing bur-
den on health care [1-4]. The prevalence for all age-
groups worldwide was estimated to be 2.8% in 2000 and
predicted to increase to 4.4% in 2030 [5]. Among adults
in the US, the prevalence of undiagnosed diabetes is cur-
rently 4.1% and prediabetes a staggering 35.6% [6]. Type
II diabetes is associated with three main glycaemic dis-
orders: chronic hyperglycaemia; glycaemic variability;
and iatrogenic hypoglycaemia [7], and also (frequently)
comorbidities including dyslipidemia (high cholesterol
levels) [8-11] and hypertension [12,13]. It has also been
suggested that with disturbed lipid metabolism, lipid
dysregulation precedes the hyperglycemia and increased* Correspondence: resia.pretorius@up.ac.za; dbk@manchester.ac.uk
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unless otherwise stated.insulin resistance is found in type II diabetes [14-17].
All of the comorbidities are potentially responsible for
the cardiovascular and other complications [18,19].
Compared with individuals without diabetes, patients
with type II diabetes have a considerably higher risk of
cardiovascular morbidity and mortality [12,20-26]. The
following paragraphs will briefly discuss systemic in-
flammation, RBC structure and fibrin clot structure in
type II diabetes.
Diabetes is associated with (low-grade) systemic in-
flammation [27-29]. Table 1 inflammatory markers and
their respective levels, that increased or decreased in
diabetes. Suggested chronological events leading to vas-
cular dysfunction in type II diabetes are summarized in
Figure 1. We know that there are important links be-
tween oxidative stress, a changed inflammatory marker
profile (inflammation), the development of diabetes type
II as well as, ultimately, vascular dysfunction:al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Selected references showing a changed
inflammatory marker profile in diabetes type II
individuals
Inflammatory marker Selected references
Low Protein C [36,42]
High levels of coagulation factors







Iron (increased serum ferritin levels) [64-89].
Increased interleukin-6 [44,45,53,62,90]
Increased thromboxane A2 [91,92]
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oxidative stress.
 Dysregulated iron levels are known to cause
oxidative stress [30-34].
 Type II diabetes and oxidative stress is closely
associated with chronic inflammation [35].
 Individuals with diabetes (and cardiovascular
disease) demonstrate hypercoagulability [36,37] and
hypercoagulability is key to inflammation [38].Figure 1 Suggested chronological events in type II diabetes. Inflammatory
oxidative stress (2); resulting in chronic (systemic) inflammation (3); that have be
to 4 have all been found in diabetes type II (5); 1 to 5 are early indicators of vas Ultimately, changed inflammatory marker levels,
hypercoagulability and chronic inflammation, serve
as early indicators of vascular dysfunction [39-41]
see Table 1.
Erythrocytes (RBCs) and atypical fibrin fiber formation
or an altered fibrin structure are particularly common in
inflammation [93-98]. Also, abnormalities of high blood
glucose in the context of insulin resistance, and relative
insulin deficiency, may disturb the architecture and
functions of RBCs at molecular scale [99]. Membrane
cholesterol has also been shown to alter the fluidity and
bending stiffness of RBCs [100,101]. Previous studies
suggest that RBC rheology is also altered in type II dia-
betes [102,103] and that hyperglycaemia has multiple
effects on RBCs, including glycation of haemoglobin,
reduced deformability and reduced lifespan [104]. It was
also shown that an improvement in erythrocyte deform-
ability from type II diabetes correlates with an improved
glycaemic control [105]. Recently, we have also shown
that RBCs in type II diabetes have a changed shape, as
well as a decreased membrane roughness [93,94,106]
and that RBCs can rapidly adapt in a changed environ-
ment, including during an addition of glucose to healthy
RBCs [107].
Similar to changes in RBC, fibrin levels and thrombin
generation are also changed, and it was indicated thatmarkers that are known to be dysregulated in diabetes (1); and to cause
en associated with hypercoagulability (4). Dysregulations, as indicated by 1
cular dysfunction (6). Literature references are given in Table 1.
Table 2 Medication typically administered to diabetes type II patients and possible effects on erythrocytes (RBCs) and fibrin clots
Medication Selected references
Dyslipidemia (cholesterol) medication (statins)
Simvastatin (Zocor®) and Atorvastatin (Lipitor®) Improve clot permeability and clot structure and enhanced fibrin clot lysis [109-113].
An increase in glycolysis metabolite concentrations and glucose-6-phosphate
dehydrogenase activity in rat RBCs [114].
Increased erythrocyte fluidity [115,116] and deformability [100,117].
Reversed alteration in RBC plasma membrane properties, including lipid peroxidation [101,118].
Blood sugar control
Antihyperglycemic drug dimethylbiguanide (Metformin®/Glucophage®) Improves clot structure and hypercoagulability [119,120],
Improves clot lyses [121,122].
Actraphane® (mixture of fast-acting insulin and long-acting insulin) No evidence of any influence on RBCs or fibrin clot structure/fibrinolysis.
Actrapid® (human soluble insulin)




Coversyl® (active ingredient is perindopril arginine which is a angiotensin converting
enzyme (ACE) inhibitor)
No evidence of any influence on RBCs or fibrin clot structure/fibrinolysis.
Amlodopine® (calcium channel blockers)
Carvedilol® (beta and alpha adrenoceptor blocker with antioxidant activity) Improves the endothelial fibrinolytic activity [123].
Scavenger effect on free radical generator-induced RBC membrane damage [124] and
enhances antioxidant defense mechanisms in RBCs [125].
Adalat® ((nifedipine) calcium channel blocker) Antithrombotic activity exhibitor [126] and improves fibrinolytic activity [127,128].
Anti-clotting medication
Aspirin® (acetylsalicylic acid) Aspirin increases fibrin clot porosity and susceptibility to lysis [111]; antiplatelet effect [129-131];
Disprin® (brand name for Aspirin) increase the level of sphingosine-1-phosphate and ceramide in erythrocytes [129]
perturbing RBC bilayer structures [132].
Reduce risk of thrombosis [133-137].
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denser fibrin clots of reduced lysability in type II dia-
betes [108]. A denser clot structure therefore results
both from this changed fibrin concentration and throm-
bin generation [95,96].
Because type II diabetes is associated with dyslipidemia
and hypertension, and most patients use medication to
treat these co-morbidities; the medications typically pre-
scribed are shown in Table 2. Here we also note evi-
dence that suggests changes that the medication might
have on RBC or fibrin structure.
We have previously shown that there are profound
changes in the hematological, and in particular, the
erythrocyte and coagulation system in various inflamma-
tory conditions where iron levels are increased (particu-
larly serum ferritin levels) (see [139-144]). In view of this,
in the current work, we studied the clot structure and
erythrocyte structure of patients with type II diabetes. InTable 3 Demographic data from healthy individuals
Sample
number






1 F 45 16.8 3 22
2 M 61 32.5 2.6 50
3 F 55 20 2.4 33
4 F 56 19.5 3.1 25
5 F 40 10 2.8 14
6 F 56 12.8 2.6 20
7 M 58 10.2 2.7 15
8 F 48 17.2 2.8 25
9 F 55 25.1 2.5 40
10 F 52 14.8 2.2 27
11 F 45 31.6 2.7 47
12 F 40 9.6 2.9 13
13 F 80 7.6 2.7 11
14 M 61 24.9 2.5 40
15 M 51 10.8 2.8 15
16 M 70 17 2.9 23
17 M 66 29.5 2.8 42
18 M 61 7 2.2 13
19 M 56 16.2 1.7 38
20 F 58 13.6 2.4 23
21 F 51 24.2 3.3 29
22 F 58 15.9 2.4 27
23 F 27 21.2 2.6 33
24 M 75 14.9 2.3 26
25 F 56 20.2 2.9 28
Bold values are above and italic values below the reference (normal) range.addition, we also investigated whether two iron chelators,
deferoxamine mesylate (DFO) and deferasirox (DFX) have
an effect on the RBC and fibrin clot structure.
Materials and methods
Type II diabetes and healthy individual profiles
Ethical clearance was obtained from the Health Sciences
Ethical Committee of the University of Pretoria. Healthy
individuals were screened and chosen to participate in the
study if they did not have any chronic condition, did not
smoke or if female, use any hormone replacement or
contraception. Diabetic individuals were chosen randomly
from the diabetic clinic at the Steve Biko Academic Hos-
pital. The patients were diagnosed according to the
SEMSDA guidelines (http://www.semdsa.org.za/images/
2012_SEMDSA_Guideline_July_FINAL.pdf). These guide-
lines follow the American Diabetes Association (ADA) cri-
teria (classification and diagnostic criteria for diabetesaturation
50%
Serum ferritin (ng.mL-1)






























Table 4 Demographics, iron, HbA1c levels and medication usage of Type II diabetes patients
Sample
number
























1 M 68 25.5 3.6 28 67 x x x x
2 M 56 49 3 65 86 11.9 x x
3 M 71 28.1 2.2 51 210 8.3 x x
4 M 80 15.5 2.6 24 96 7 x x x x
5 M 37 18.5 2.8 26 191 7.6 x
6 M 56 10.6 2.7 16 39 7.7 x x
7 F 71 19.9 2.3 35 20 8 x x x x
8 F 48 15.1 3.3 18 46 6.2 x x x x
9 F 70 5.2 3.9 5 7 7.5 x x
10 F 82 33.6 3 45 101 8.9 x x x x
11 M 62 25.6 2.3 45 202 5.9 x x
12 M 71 17.8 2.4 30 243 10.5 x x x x
13 M 70 19.7 2.2 36 75 10.4 x x
14 F 58 36.5 2.9 50 164 6.0 x
15 F 61 18.6 2.8 27 29 8.2 x x
16 M 56 32.1 2.9 44 152 8.6 x x x x
17 M 42 40.7 2.3 71 217 13.6 x
18 F 62 16.2 4.1 16 24 10.6 x x x x
19 M 72 19.8 2.1 38 332 6.7 x x x x
20 M 59 18.5 2.8 26 191 ? x x
21 M 75 14 1.7 33 218 6.6 x x x x
22 M 41 28.2 3 38 235 8.3 x x x x
23 F 81 23.8 2.3 41 62 9 x x x x
24 M 41 33.4 2.7 49 101 5.5 x x x x
25 M 80 39.5 2.7 59 142 6.8 x x x
26 M 64 13.2 2.3 23 50 ? x x
27 M 63 22.9 2.4 38 265 10.2 x x x x x
28 F 49 7.1 3.4 8 12 6.8 x x x x
29 M 72 25.3 2.4 42 386 6.7 x x x x











Table 4 Demographics, iron, HbA1c levels and medication usage of Type II diabetes patients (Continued)
31 M 40 14.5 2.4 24 96 8.7 x x
32 M 55 10.3 2.2 19 88 5.8 x x x
33 F 62 BLOOD CLOTTED 8.2 x x
34 M 52 25.9 3 35 155 x x
35 F 59 18.5 2.5 30 125 11.6 x x x
36 F 58 16.5 2.5 26 79 6.0 x x x x x
37 F 62 14.1 2.9 19 64 10.2 x x x x
38 M 60 6.1 2.6 9 93 7.5 x x x x x
39 F 57 24 2.7 36 60 8.0 x x x x x
40 F 63 31.4 2.5 50 77 7.6 x x x x
41 M 59 15.4 2.8 22 151 8.5 x x x x
42 M 73 29.5 2.9 51 154 8.0 x x x
43 F 58 20.3 2 41 81 10.6 x x x x
44 F 66 28.6 2.6 44 359 10.0 x x x x
45 M 60 18 2.4 30 192 12.2 x x x x
46 F 69 9.6 2.3 17 74 7.4 x x x x
47 M 62 21.1 3.1 27 28 9.2 x x x
48 M 58 28.2 2.8 40 605 11.9 x x x x x
49 F 62 12.4 2.2 23 58 11.3 x x x x
50 M 61 23 1.9 48 1097 6.9 x x x x
51 M 73 54.9 2.4 92 100 x x x x
52 F 45 8 3.7 9 9 11.6 x x x x
53 F 62 42.3 2.4 71 198 8 x x
54 F 53 BLOOD CLOTTED 10.9 x x x x
55 F 55 13.1 2.2 24 189 6.3 x x x x x
56 M 56 27 2.6 42 64 12.1 x x x x
57 F 70 17.8 3 24 23 11.6 x x x x
58 F 59 34.1 2.7 51 56 5.8 x x x x
59 M 66 32.3 2.7 48 123 11.9 x x x x x
60 F 54 BLOOD CLOTTED 15.1 x x x
61 M 65 19.3 2.8 28 57 7.0 x x x











Table 4 Demographics, iron, HbA1c levels and medication usage of Type II diabetes patients (Continued)
63 F 59 20.4 3.6 23 149
64 F 64 7.3 2.3 13 82 9.0 x x x
65 M 32 16.8 3.2 21 58
66 M 52 129.6 checked 3.2 >95 55 8.1 x x x x x
67 M 52 14.5 2.3 25 151 12.2 x x x
68 F 49 14.2 2.7 21 17 13.5 x x
69 F 42 6 3.4 7 9 8.3 x x x x











Table 5 Average axial ratios of the groups and significant differences between the groups
Healthy individuals
(no products added) (N = 25)
Untreated Diabetes
(DIAB) (N = 69)
Diabetes with Deferasirox
(DFX) (N = 69)
Diabetes with Deferoxamine
(DFO) (N = 69)
Average age and ± SD 55 ± 11 59 ± 11
Cells analysed (N) 3265 4365 4271 4369
Axial ratio average and ± SD 1.14 ± 0.15 1.25 ± 0.27 1.24 ± 0.26 1.27 ± 0.27
SIGNIFICANT DIFFERENCE BETWEEN GROUPS (p-values shown)
Healthy/Diab Diab/DFX Diab/DFO DFX/DFO Healthy/DFX Healthy/DFO
1.1E-56 4.7E-02 2.6E-04 2.6E-04 2.9E-83 2.0E-02
Data provided for healthy individuals compared with untreated diabetes, diabetes treated with deferasirox (DFX) and deferoxamine (DFO). Untreated diabetes
results were also compared (comparison done on a paired basis) with diabetes treated with DFX and DFO.
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define type II diabetes [145,146]. Citrated blood was col-
lected for morphology studies and full iron profiles tests
were done on both healthy and diabetic individuals.
Plasma iron levels, HbA1c (Hemoglobin Alc) and medica-
tion were noted for each of the diabetes individuals (dis-
cussed later in detail in tables).
Chelator addition to blood samples
Microscopy techniques were done with blood from dia-
betic patients with and without the addition of deferoxa-
mine (DFO) and deferasirox (DFX), and with and
without the addition of thrombin (final concentration
chelator in whole blood were 3.33 mM and where
thrombin was added, was 2.5 mM). To ensure a signifi-
cant effect, we added an excess of each chelator; stoi-
chiometric principles will ensure the full chelation of
any unliganded iron present in whatever form. The solv-
ent for both the chelators was DD H2O. Chelators were
added to whole blood (WB) and left to react for 3 min-
utes. The kinetics of the chelators are virtually instantan-
eous and the potential for sequestration of the chelators
by e.g. albumin is precisely why we added an excess of
these reagents. When thrombin is added an extensive fi-
brin network is created around trapped RBCs. TheseFigure 2 Blood smears from two healthy individuals, showing axial ra
mL−1 B) male: 58; serum ferritin: 208 ng.mL−1. Scale bar = 5 μM.WB preparation methods were done for all microscopy
techniques (described in the following paragraphs).
Light microscopy of erythrocytes
LM was used to study the axial ratios of RBCs, using
100 × magnification (with and without DFX and DFO).
10ul of WB was used to make a thin smear on a micro-
scopic glass slide, this smear was left for 24 hours to air
dry followed by fixing for 5 minutes in 100% methanol
and left to air dry for 30 minutes. The smears were
stained again for 4 minutes with Löffler’s methylene
blue, and rinsed under running water followed by air-
drying for 30 minutes. The final staining step involved
staining for 30 seconds in Eosin Y-solution 0.5% aque-
ous, and rinsing with running water. Slides were viewed
using a Nikon Optiphod transmitted light microscope.
Axial ratio determination of erythrocyte shape
Axial ratios were determined from the LM micrographs,
with the use of a program written in the C# program-
ming language. The longest axis from each RBC was
determined, referred to as the major axis, after which a
perpendicular line was drawn in the centre of the major
axis to establish the minor axis length. The axial ratio
for each cell was obtained by dividing the major axistio positions used for calculations. A) Male: 60; serum ferritin: 48 ng.
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 9 of 20length by the minor axis length; a value of 1 represents a
perfect circle.
Scanning electron microscopy (SEM) of erythrocytes
High magnification SEM analyses were used to look at
RBC structure and membrane surface. 20 μL of the fixed
WB was dropped on a small glass coverslip to make
smears, dehydrated, dried, mounted and coated with car-
bon according to previously described methods [93]. A
Zeiss ULTRA Plus FEG-SEM with InLens capabilitiesFigure 3 Light microscopy smears of diabetic patients before and aft
and right: treated with deferoxamine (DFO). Patient detail is shown in Tablwas used to study the surface morphology of erythro-
cytes, and micrographs were taken at 1 kV.
Atomic force microscopy of erythrocytes
Sample preparation was done according to previously
described methods [143]. Characterization of RBCs was
performed with a commercial AFM system (Dimension
Icon with ScanAsyst, Bruker, USA) using the PeakForce
QNM (Quantitative Nanomechanical Property Mapping)
imaging mode [147]. At every pixel point a rapid force-er treatment. Left: untreated; middle: treated with deferasirox (DFX)
e 6. Scale bar = 5 μM.
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 10 of 20distance curve is performed and as the cantilever’s de-
flection sensitivity and spring constant is calibrated be-
fore measurements, the curve can be analysed
quantitatively to obtain a series of specific property maps
of the sample. A retract curve is used to calculate modu-
lus and adhesion images (slope of the curve and the
minimum of the curve respectively) [141,143,148], the
variation between the zero and maximum force is used
to calculate deformation and the area between the ap-
proach and retract curve can be used to calculate energy
dissipation [149]. The slope of the curve was fit, using
the Derjaguin–Muller–Toporov (DMT) Model to deter-
mine the Young’s modulus (a measure of the stiffness of
an elastic material) [141,150]. Silicon Nitride probes
(TAP525 – MPP 13120–10, Bruker, USA) with a nom-
inal force constant of 200 N.m-1, a resonant frequency
between 430 and 516 kHz (measured by the manufac-
turer), and a nominal tip radius of 15 nm were employed
in all AFM measurements.
From the diabetes sample, RBCs from the first 22 dia-
betic patients were analysed using AFM analysis, before
and after exposure to the 2 chelators. Ten cells from
each sample were analysed by selecting a 1 μm by 1 μm
scan area on the periphery of the RBC and performing
128 by 128 data points of individual force curve mea-
surements with a peak force of 6 μN. The periphery ofTable 6 Diabetes patient detail for light microscopy axial rati
AVERAGE
AXIAL RATIOS
P1 P2 Gender Age Iron
11.6
DIABETES 47 1.24 0.006 0.009 M 62 21.1
DFX 1.15
DFO 1.17
DIABETES 42 1.14 0.05 0.28 M 73 29.5
DFX 1.14
DFO 1.17
DIABETES 62 1.24 0.25 4.2 × 10−7 F 56 16.6
DFX 1.28
DFO 1.45
DIABETES 55 1.16 0.035 0.001 F 55 13.1
DFX 1.21
DFO 1.25
DIABETES 50 1.18 0.035 0.73 M 61 23
DFX 1.14
DFO 1.17
DIABETES 66 1.33 5.8 × 10−7 3.9 × 10−7 M 52 129
DFX 1.15
DFO 1.11
P-values: P1 (axial ratios of untreated diabetes RBCs versus DFX-treated) and P2 (ax
was taken as ≤ 0.05; comparisons done on a paired basis) (Figure 3). Bold values arethe cells was chosen as not to be affected by the possible
differences in concavity of the RBCs. The scans were
performed at 0.6 Hz, which translates to a tip velocity of
1.2 μm/s and 50 force curves were chosen randomly
within the stated area. Offline software (NanoScope
Analysis version R3, Bruker, USA) was used to process
the force curves and fit the modulus model to the
unloading portion of the curve. The goodness of fit (R2)
between the modulus model and the data given by the
acquired curve is determined by calculating the ratio of
explained variation to total variation in the dataset; only
force curves with a goodness of fit so defined of 0.85
and above were used for modulus measurements. The
statistical significance of the difference between calcula-
tions was determined using one-way analysis of variance.
A P-value of less than 0.05 relative to the null hypothesis
was considered to be ‘significant’ (cf. [151]), P-values are
noted and boxplots drawn, together with descriptive sta-
tistics. A box plot was calculated using MS-Excel, to-
gether with the add-in template downloadable from
http://www.vertex42.com/.
Scanning electron microscopy of fibrin networks
10 μL platelet rich plasma (PRP) was mixed with 10 μL
human thrombin provided by the South African Blood














.6 3.2 >95 55
ial ratios of untreated diabetes RBCs versus DFO-treated) (significant p-value
above and italic values below the reference (normal) range.
Figure 4 Axial ratios of the erythrocytes from controls and diabetics. As indicated in Table 5, there were significant differences in the axial ratios of
diabetes vs controls, whether iron chelators were present or absent. A. Relationship between axial ratio and its standard deviation. B. Direct comparison
between patients and controls. In B the values on the abscissa (only) are ‘jittered’ to make them easier to see.
Figure 5 Whole blood of healthy individual, with added
thrombin, to create an extensive fibrin network around RBCs.
Male: 61; serum ferritin: 48 ng.mL−1. Scale Bar = 1 μM.
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 11 of 20and smears washed and fixed in 4% formaldehyde.
Smears were prepared as described for RBCs and also
viewed using Zeiss ULTRA Plus FEG-SEM with InLens
capabilities. Fibrin fiber thickness were measured with
ImageJ (ImageJ is a public domain, Java-based image
processing program developed at the National Institutes
of Health: http://rsbweb.nih.gov/ij/).
Results
This study used 25 age- and gender-controlled healthy
individuals (see Table 3) and 69 individuals with type
II diabetes. The average age of healthy individuals was
55 (SD ± 11), while the average age of the diabetic
individuals was 59 (SD ± 11). The current randomly
selected type II diabetic population, in addition to
their anti-diabetic medication, are on medication for
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 12 of 20dyslipidemia and hypertension as well (see Table 4).
Despite their anti-diabetic medications, very few indi-
viduals showed HbA1c (Hemoglobin Alc) within the
normal ranges, suggesting poorly controlled diabetes.
In some patients, there were also abnormal iron levels
(Table 4).Figure 6 Whole blood from diabetic patients before and after treatment
Table 7 shows the detail of the diabetic patients (sample numbers of diabetic pLight microscopy
Light microscopy of smears from typical healthy indivi-
duals, with their axial ratio positions indicated, is shown
in Figure 2. Light microscopy statistics of the average
RBC axial ratios of within group analysis are shown in
Table 5. Figure 3 shows smears from diabetes patients. Left: untreated; middle: Deferasirox (DFX) and right: deferoxamine (DFO).
atients shown on micrographs) shown in this figure. Scale Bar = 1 μM.
Figure 7 Boxplot showing the variation of the Young’s modulus values of erythrocyte membrane stiffness, after the treatment of
whole blood of diabetics with iron-chelating agents. Young’s modulus median values did not vary significantly between the diabetes and
two chelating agents (indicated in red in the figure).
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 13 of 20before and after treatment with the 2 chelators (left: un-
treated diabetes; middle: DFX; right: DFO) Smears were
chosen that represents the sample, e.g. normal iron
levels, increased iron levels and whether addition of che-
lators showed a significant P-value (or not) (see Table 6);
for specific details of the patients shown in Figure 3. A
relationship between the RBC axial ratios and SD for the
healthy controls, untreated diabetes and treated with
DES and DEF was noted, and is illustrated in scatter
plots (see Figure 4A and B).Table 7 Diabetic patient details of micrographs from the SEM
Gender Age Iron (μmol.L−1)
11.6-31.3
DIABETES 29 M 72 25.3
DIABETES 44 F 66 28.6
DIABETES 50 M 61 23
DIABETES 45 Yes M 60
DIABETES 46 F 69 9.6
DIABETES 49 F 62 12.4
Bold values are above and italic values below the reference (normal) range.Scanning electron microscopy (SEM) of erythrocytes
Figure 5 shows whole blood with added thrombin, which
serves to create an extensive fibrin network around
RBCs from a typical healthy individual. Figure 6 shows
whole blood from diabetic patients before and after
treatment where left, shows untreated WB, middle,
shows WB treated with DFX and right, shows whole
blood treated with DFO. Table 7 shows the detail of the
diabetic patients shown in Figure 6. WB with added













Table 8 Statistical analyses of membrane stiffness as
measured by Young’s modulus values of the diabetic
group and treated groups
Group Mean Young’s modulus SD P-value
Healthy individuals 46710 39210 -
Diabetes 56483 64418 1.15E-13
Diabetes + DFX 51238 58225 2.7E-06
Diabetes + DFO 50446 36073 1.6E-10
(Diabetes p-value is from a pairwise comparison with the healthy individual
group. DFX and DFO diabetes-treated p-values are from pairwise comparisons
with the diabetic group).
Pretorius et al. Cardiovascular Diabetology  (2015) 14:30 Page 14 of 20the typical discoid RBCs. The RBCs keep their character-
istic shape. However, in the diabetic populations, the
RBC structure is compromised and in all the samples,
the RBCs twist and fold easily in the presence of the fi-
brin fibres In the presence of the 2 chelators, it seems as
if the RBCs do regain their typical discoid shape. See
middle and right column micrographs of Figure 6. SEM
and LM axial ratio analyses both showed that RBC
shapes are changed in untreated RBCs of diabetic indivi-
duals (left column), but that chelator treatment seems to
stabilize RBC shape and membranes (middle and right
columns) (also noted in the AFM results shown in later
paragraphs).
Atomic force microscopy of erythrocyte membranes
A significant increase in the Young’s modulus (stiffness)
was seen in the RBCs of 22 randomly selected diabeticFigure 8 Young’s modulus (stiffness) measurements to show trends i
DFX and DFO.patients, whose blood was treated with the 2 chelators.
This reflects a decrease in elasticity and an assumed
altered functionality in these cells. Treatment with either
DFX or DFO decreased the Young’s modulus values to-
wards more normal values, indicating a possible im-
provement in the elasticity of the cells (see Figure 7 and
Table 8).
However, when the elasticity measurements are com-
pared individually after treatment with the iron chelating
agents a more complex picture emerges, due to the sub-
stantial variation in the two cohorts. Although on aver-
age the iron chelators caused a significant increase in
elasticity, more than 50% of the diabetic group treated
with DFX and almost 40% treated with DFO showed an
increase in the elastic (see Figure 8).
Scanning electron microscopy of fibrin network
Figure 9 shows plasma with added thrombin to create
an extensive fibrin network from a typical healthy indi-
vidual. Figure 10 shows whole blood from diabetic
patients before and after treatment, where column A
shows untreated WB, column B shows WB treated with
DFX and column C shows WB treated with DFO.
Smears were chosen that represents the sample, e.g. nor-
mal iron levels, increased iron levels and whether
addition of chelators showed a significant P-value (or
not); see Table 7 for specific details of the patients
shown in the figure. Typically, fibrin forms individually
visible fibres. However, in the presence of inflammation,
the fibrin clots abnormally, to form finer fibres and in
some cases, a continuous layer, where individual fibresn 19 of the individual diabetic erythrocytes after treatment with
Figure 9 Plasma from a healthy individual, with added thrombin, to create an extensive fibrin network. Male: 58; serum ferritin: 208 ng.
mL−1. Scale Bar = 1 μM.
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betic patients [95,96]. With the addition of the 2 che-
lators, fibrin nets with visible individual fibres are
seen. This was found irrespective of increased SF
levels (see Table 9) and we have argued [139] that
serum ferritin – which not even exist as it is it not an
extracellular iron transporter – is probably devoid of
much iron anyway.
Discussion
Type II diabetes mellitus is a metabolic disorder of
deranged fat, protein and carbohydrate metabolism
resulting in hyperglycaemia from insulin resistance and
inadequate insulin secretion [152]. This condition is very
difficult to treat and even in countries like the USA,
fewer than 50% of patients achieve the HbA1c goal of <
7% set by the American Diabetes Association [152,153].
One of the reasons might be poor adherence to treat-
ment regimes [154-156], as well as poor diet and know-
ledge regarding nutrition [157].
In the current work, we noted a changed RBC shape
and membrane structure, as well as a matted fibrin fibre
structure. Previously, we suggested that this might be
due to oxidative stress and increased iron levels [93].
Oxidative stress in diabetic subjects, including those
with cardiovascular manifestations, may also be attribu-
ted to the hyperglycaemia which modifies the RBC
membrane dynamic and electrokinetic properties when
compared to healthy controls [158].
In the present study, we noted that the axial ratio of
the RBCs from diabetic patients was significantly greaterthan that of matched controls, as seems to occur in a
variety of inflammatory diseases [140,143,159]. Iron dys-
regulation is often intimately involved and unliganded
iron can act in one of two main ways, viz simply by
electrostatics or via its ability to catalyse hydroxyl rad-
ical formation with covalent modification (by hydroxyl
radicals) of proteins and other macromolecules
[139,141,160]. The former, but not the latter, may be
reversed by iron chelators [139]. In the present study,
the chelators had no effect on the axial ratios, consist-
ent with the view that in the chronic conditions of dia-
betes the changes are mainly due to hydroxyl radical
formation. However, the chelators did have effects on
the detailed morphology of the RBCs, suggesting some
contribution of electrostatic forces. AFM measure-
ments indicated that the membrane stiffness of the
RBCs of diabetics was significantly greater than that of
controls, and that overall this could be alleviated by
the addition of iron chelators. However, a detailed
analysis showed that this was quite patient-specific.
Recently, Berndt-Zipfel and coworkers, showed that
RBC deformability (measured using a laser-assisted op-
tical rotational cell analyzer by determining the elong-
ation index) was also changed in type II diabetes, and
that an improved RBC deformability correlate of
improved glycaemic control [105]. The current patient
sample mostly had very poor glycaemic control, and
this might partly be the reason for limited RBC shape
and deformability improvement.
In a similar vein, the ultrastructure of the fibrin clots
formed in the blood of diabetic patients following
Figure 10 Fibrin formed in plasma from diabetic patients before and after treatment. Left: untreated; middle: Deferasirox (DFX) and right:
desferrioxamine (DFO).
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ture relative to those from the controls, much as we
have seen before in a variety of inflammatory diseases.
In this study, the chelators could act to make the fibrin
morphology much more like those of the controls, con-
sistent with the view that at least of these effects weredue to the presence of unliganded iron acting electrosta-
tically to modify fibrinogen and its behavior during
polymerization to form fibrin.
Overall, we note, as we have before in a number of in-
flammatory diseases [139,141,143,159,160] that patients
with type II diabetes manifest this via significant
Table 9 Diabetic patient details of micrographs from the SEM analysis shown in Figure 10







M = 20-250 F = 10-120
DIABETES 29 M 72 25.3 2.4 42 386
DIABETES 44 F 66 28.6 2.6 44 359
DIABETES 50 M 61 23 1.9 48 1097
DIABETES 32 M 55 10.3 2.2 19 88
DIABETES 46 F 69 9.6 2.3 17 74
DIABETES 49 F 62 12.4 2.2 23 58
Bold values are above and italic values below the reference (normal) range.
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and in the nature of the fibrin fibres formed upon the
addition of thrombin. We do not yet know whether
these morphological changes have prognostic (as well
as diagnostic) significance, but it is clear that lowering
the amounts of labile iron are likely to be of benefit, as
serum ferritin is an important disease marker, and
implicated in most inflammatory conditions. Previously,
we argued that and it is mainly a leakage product from
damaged cells [139]. There are therefore possible clin-
ical implications for “labile” (chelatable) iron in the
thrombin-elicited fibrin formation in the plasma of dia-
betic patients, and also the elasticity of RBCs, possibly
associated with serum proteins.
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